WallStSmart

Cogent Biosciences Inc (COGT)vsBeiGene, Ltd. (ONC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).

COGT

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: -0.57

ONC

Buy

64

out of 100

Grade: C+

Growth: 9.3Profit: 6.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COGT.

ONCUndervalued (+80.1%)

Margin of Safety

+80.1%

Fair Value

$1767.21

Current Price

$346.51

$1420.70 discount

UndervaluedFair: $1767.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COGT0 strengths · Avg: 0/10

No standout strengths identified

ONC4 strengths · Avg: 8.8/10
EPS GrowthGrowth
166.7%10/10

Earnings expanding 166.7% YoY

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Revenue GrowthGrowth
29.6%8/10

Revenue surging 29.6% year-over-year

Areas to Watch

COGT4 concerns · Avg: 3.5/10
Price/BookValuation
12.3x4/10

Trading at 12.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

ONC2 concerns · Avg: 2.0/10
P/E RatioValuation
64.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : COGT

COGT has a balanced fundamental profile.

Bull Case : ONC

The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bear Case : COGT

The primary concerns for COGT are Price/Book, EPS Growth, Profit Margin.

Bear Case : ONC

The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 64.1x leaves little room for execution misses.

Key Dynamics to Monitor

COGT profiles as a value stock while ONC is a growth play — different risk/reward profiles.

ONC carries more volatility with a beta of 0.52 — expect wider price swings.

ONC is growing revenue faster at 29.6% — sustainability is the question.

ONC generates stronger free cash flow (596M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (64/100 vs 23/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cogent Biosciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge, Massachusetts.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?